Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies

References

• Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344–7.
   PubMed Web of Science ®Google Scholar
• Gerami P, Walling HW, Lewis J, Doughty L, Southeimer RD. A systematic review of juvenile-onset-clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157:637–44.
   PubMed Web of Science ®Google Scholar
• Tansley SL. Antibodies in juvenile-onset myositis. Curr Opin Rheumatol. 2016;28:645–50.
   PubMed Web of Science ®Google Scholar
• Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine. 2013;92:223–43.
   PubMed Web of Science ®Google Scholar
• Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280:24–38.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology. 2015;54:784–91.
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011;158:675–7.
   PubMed Web of Science ®Google Scholar
• Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23:496–502.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–8.
   PubMedGoogle Scholar
• Kobayashi I, Tozawa Y, Ueki M, Takezaki S, Watanabe S, Iwafuchi H, et al. Tacrolimus in combination with methotrexate and corticosteroid for the treatment of child-onset anti-signal recognition particle antibody-positive necrotizing myopathy. Scand J Rheumatol. 2017;46:409–10.
   PubMed Web of Science ®Google Scholar
• Sato S, Uejima Y, Nanbu M, Suganuma E, Takano T, Tanaka R, et al. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis. Mod Rheumatol. 2017;27:652–6.
   PubMed Web of Science ®Google Scholar
• Hamada M, Tanaka I, Sakurai Y, Hosono Y, Mimori T. Juvenile polymyositis associated with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody in a 13-year-old girl. Mod Rheumatol. 2017;27:541–4.
   PubMed Web of Science ®Google Scholar
• Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther. 2013;15:211.
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25–34.
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu W, Guo Z, Sun L, Kuwana M. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese polymyositis/dermatomyositis. Clin Rheumatol. 2015;34:1627–31.
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res. 2016;68:689–94.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kawabata D, Yukawa N, Yoshifuji H, Usui T, Tanaka M, et al. Severe subcutaneous generalized edema in a patient with dermatomyositis. Mod Rheumatol. 2007;17:171–3.
   PubMedGoogle Scholar
• Saygi S, Alehan F, Baskin E, Bayrakci US, Ulu EM, Ozbek N. Juvenile dermatomyositis presenting with anasarca. J Child Neurol. 2008;23:1353–6.
   PubMed Web of Science ®Google Scholar
• Milisenda JC, Doti PI, Prieto-Gonzalez S, Grau JM. Dermatomyositis with severe subcutaneous edema: five additional cases and review of the literature. Semin Arthritis Rheum. 2014;44:228–33.
   PubMed Web of Science ®Google Scholar
• Guffroy A, Dervieux B, Gravier S, Martinez C, Deibemer-Kaminsky J, Hachulla E, et al. Systemic capillary leak syndrome and autoimmune diseases: a case series. Semin Arhtritis Rheum. 2017;46:509–12.
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Ono S, Kawamura N, Okano M, Kobayashi K. Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis. Pediatr Int. 2001;43:109–11.
   PubMed Web of Science ®Google Scholar
• Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, et al. Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology. 2014;53:686–95.
   PubMed Web of Science ®Google Scholar
• Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60:1825–30.
   PubMedGoogle Scholar
• Kang EH, Kuwana M, Okazaki Y, Lee EY, Lee YJ, Lee EB, et al. Comparison of radioimmunoprecipitation versus antigen-specific assay for identification of myositis-specific autoantibodies in dermatomyositis patients. Mod Rheumatol. 2014;24:945–8.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013;8:e60442.
   PubMed Web of Science ®Google Scholar
• Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013;65:1307–15.
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;2014:290797.
   PubMed Web of Science ®Google Scholar
• Sugie K, Tonomura Y, Ueno S. Characterization of dermatomyositis with coexistence of anti-Jo-1 and anti-SRP antibodies. Intern Med. 2012;51:799–802.
   PubMed Web of Science ®Google Scholar
• Naniwa T, Tamechika S, Okazaki Y, Maeda S, Kuwana M. Coexistence of anti-melanoma differentiation-associated gene 5 and anti-aminoacyl-transfer RNA synthetase antibodies in a patient with dermatomyositis and rapidly progressive and relapsing interstitial lung disease. Modern Rheumatol Case Rep. 2017;1:3–8.
   Google Scholar
• Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, et al. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology. 2017;88:493–500.
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M, et al. Anti-HMGCR antibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J Rheumatol. 2017;44:488–92.
   PubMed Web of Science ®Google Scholar
• Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280:8–23.
   PubMed Web of Science ®Google Scholar